On December 24, 2020 Foresee pharmaceuticals (TPEx: 6576.TWO) ("Foresee") reported that it has successfully completed an underwritten public offering of 15,000,000 shares of its common stock to the public at a price of NT$88 per share (Press release, Foresee Pharmaceuticals, DEC 24, 2020, View Source [SID1234573254]). The aggregate gross proceeds to Foresee from the offering were approximately US$47 million (NT$1.32 billion).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The proceeds of the Public Offering will be used for general corporate purposes, which include supporting Foresee’s existing drug research and development programs – such as FP-025, for which a Phase II/III clinical trial IND application was recently submitted to the FDA for the treatment of acute respiratory distress syndrome (ARDS) in COVID-19 patients.

In addition to the progress of FP-025, Foresee’s Camcevi 42 mg, a ready-to-use 6-month depot formulation of leuprolide mesylate, is currently under review process by the FDA and EMA, which will soon be followed by Camcevi 3-month depot; FP-045, an orally bioavailable ALDH2 activator, which previously obtained permission from the FDA to proceed with the clinical study, is planned to enter into a Phase 1/2 dose-finding study in adolescent and pediatric patients with Fanconi anemia.

Previously this year, Foresee has completed a round of private placement financing, raising approximately US$3 million (NT$90 million) by the issuance of 1,200,000 shares of common stock at a price of NT$75.